Research progress of small molecule inhibitors targeting PI3K-Akt-mTOR pathway / 中国生化药物杂志
Chinese Journal of Biochemical Pharmaceutics
; (6): 6-15, 2016.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-503636
Biblioteca responsável:
WPRO
ABSTRACT
Aberrant activation of the phosphatidylinositol 3-kinase(PI3K)-protein kinase B(PKB,Akt)-mammalian target of rapamycin(mTOR) pathway is commonly observed in human cancer and is critical for cell survival, proliferation and differentiation.A variety of small molecule inhibitors targeting PI3K-Akt-mTOR pathway are under clinical studies.This review will summarize the recent studies in terms of the PI3K-Akt-mTOR signaling pathway and cancer,research progress of the antitumor activity possessed by PI3K-Akt-mTOR inhibitors,as well as the recent research in the related field conducted by our group.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Biochemical Pharmaceutics
Ano de publicação:
2016
Tipo de documento:
Artigo